Table 1 Baseline demographics of the patients
Characteristics | Number (%) or median (range) |
|---|---|
Age, year | 72 (51–81) |
BMI, kg/m2 | 23.2 (17.9–27.8) |
PSA, ng ml | 8.2 (1.9–148) |
Prostate volume, ml | 31.0 (7.9–109.8) |
Biopsy Gleason score | |
6 | 42 (16.7) |
3 + 4 | 69 (27.5) |
4 + 3 | 49 (19.5) |
8 | 52 (20.7) |
≥ 9 | 39 (15.6) |
Clinical T stage | |
T1c | 11 (4.4) |
T2a | 133 (53.0) |
T2b | 2 (0.8) |
T2c | 42 (16.7) |
T3a | 53 (21.1) |
T3b | 10 (4.0) |
Clinical N stage | |
N0 | 243 (96.8) |
N1 | 8 (3.2) |
Risk classification | |
Low or intermediate | 105 (41.8) |
High | 83 (33.1) |
Locally advanced | 63 (25.1) |
Preoperative ADT | |
No | 154 (61.4) |
Yes | 97 (38.6) |
Preoperative MUL, mm | 11.2 (5.8–18.8) |
Postoperative MUL, mm | 10.1 (4.2–15.8) |
Approach | |
Transperitoneal | 230 (91.6) |
Extraperitoneal | 21 (8.4) |
NVB sparing | |
None | 221 (88.0) |
Unilateral or bilateral | 30 (12.0) |
PLND | |
None | 191 (76.1) |
Standard or extended | 60 (23.9) |
PUVA | 10.6 (− 5.3 to 25.2) |
Operation time, min | 168 (92–322) |
EBL, ml | 108 (0–1575) |
Pathologic T stage | |
ypT0 | 7 (2.8) |
T2 or ypT2 | 189 (75.3) |
T3 or ypT3 | 55 (21.9) |
Surgical margin | |
Negative | 192 (76.5) |
Positive | 59 (23.5) |